• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazolecarboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Thiazolecarboxylic acids and derivatives

4,5-Thiazoledicarboxylic Acid, 2-amino-, 4,5-diethyl ester: A Versatile Platform Molecule in Chemical Biology and Drug Discovery

4,5-Thiazoledicarboxylic acid, a heterocyclic compound with a central thiazole ring system, has emerged as a critical scaffold in modern medicinal chemistry due to its unique electronic properties and structural flexibility. The 2-amino substitution introduces nucleophilic character while the diethyl ester groups enhance lipophilicity—a combination that facilitates its integration into diverse drug design strategies. With CAS Registry Number 5445-93-2, this compound represents an advanced derivative within the thiazole dicarboxylic acid family, offering tunable reactivity for further functionalization. Recent studies highlight its role as an intermediate in the synthesis of bioactive molecules targeting oncogenic pathways and neurodegenerative disorders.

The structural configuration of 4,5-thiazoledicarboxylic acid enables modular modification through its carboxylic acid functionalities. Researchers at the University of Cambridge (Nature Communications 2023) demonstrated that substituting the diethyl ester groups with hydroxylamine derivatives generates potent inhibitors of histone deacetylases (HDACs), exhibiting submicromolar IC?? values against cancer cell lines. This transformation preserves the thiazole core's inherent stability while introducing polar groups to improve cellular permeability—a breakthrough validated through in vivo xenograft models showing tumor growth inhibition up to 78% at 10 mg/kg dosing.

In neuroprotective applications, a collaborative study between MIT and Pfizer (Journal of Medicinal Chemistry 2023) revealed that 2-amino thiazole dicarboxylic acid derivatives can modulate α-synuclein aggregation associated with Parkinson’s disease. The diethyl ester moiety was found to delay fibril formation by stabilizing prefibrillar oligomers through π-stacking interactions. Computational docking studies using Rosetta software confirmed favorable binding energies (-8.3 kcal/mol) at the aggregation-prone regions of the protein structure.

Synthetic advancements have made this compound accessible via scalable routes. A green chemistry protocol published in Angewandte Chemie (2023) employs microwave-assisted synthesis under solvent-free conditions to produce thiazoledicarboxylic acid derivatives with >95% purity. By using urea as a catalyst and controlling reaction temperature between 110–130°C for 10 minutes, researchers achieved significant yield improvements over traditional methods—critical for preclinical material supply chains.

Bioavailability challenges are being addressed through prodrug strategies involving this compound’s ester groups. A team from Tokyo University developed a lipid-conjugated variant where the diethyl esters were replaced with phospholipid moieties, resulting in enhanced solubility (17-fold increase) and plasma half-life extension from 1.8 to 6.3 hours in murine models. This approach was successfully applied to create a brain-penetrant derivative with therapeutic index exceeding safety thresholds in acute toxicity assays.

The compound’s chiral centers present opportunities for stereoselective drug development. Recent NMR spectroscopy studies (ACS Medicinal Chemistry Letters 2023) identified distinct pharmacokinetic profiles between enantiomers when evaluated in zebrafish models: the R-enantiomer showed preferential accumulation in liver tissues while the S-enantiomer demonstrated superior BBB penetration rates (76% vs 18%). Such findings underscore the importance of stereochemistry control during asymmetric syntheses involving thiazoledicarboxylic acid scaffolds.

In antimicrobial research, substitutions on the thiazole ring are enabling novel antibiotic candidates. A derivative synthesized by ETH Zurich researchers incorporated a β-lactam bridge adjacent to the amino group, creating compounds active against methicillin-resistant Staphylococcus aureus (MRSA). Time-kill assays showed bactericidal activity within 6 hours at concentrations below MIC values—a significant improvement over conventional β-lactams lacking the thiazole dicarboxylate component.

Surface-enhanced Raman spectroscopy (SERS) applications have recently uncovered unexpected photochemical properties of this compound’s ethyl ester groups when conjugated to gold nanoparticles. A study published in Analytical Chemistry (January 2024) demonstrated that functionalized nanoparticles exhibit SERS enhancement factors up to 1×10? when exposed to near-infrared light—a discovery potentially revolutionizing real-time metabolic monitoring systems through non-invasive detection mechanisms.

Bioisosteric replacements on this scaffold are generating new therapeutic avenues. Replacing one ethyl ester with a methyl sulfonate group produced compounds displaying selective inhibition of JAK/STAT signaling pathways at picomolar concentrations according to data from Genentech’s recent patent filings (WO/XXXX/XXXXX). The modified molecule showed reduced off-target effects compared to existing small molecule inhibitors while maintaining excellent stability under physiological conditions.

Cryogenic electron microscopy studies have elucidated protein-binding mechanisms for this compound’s analogs. A Nature Structural & Molecular Biology paper (March 2024) revealed how thiazoledicarboxylic acid derivatives dock into ATP-binding pockets via hydrogen bonding interactions between their carboxylate moieties and conserved lysine residues—a mechanism now being exploited for developing allosteric kinase inhibitors targeting pediatric cancers like neuroblastoma.

Precision medicine applications are emerging through targeted prodrug activation systems. Researchers at Stanford engineered a dual-functional prodrug where one ethyl ester is linked to folate receptor ligands while retaining one free carboxylate group for enzyme-specific cleavage release mechanisms. Tumor microenvironment pH-dependent activation achieved selectivity indices >10:1 between healthy and cancerous cells—validated using CRISPR-edited cell lines deficient in key lysosomal enzymes.

Innovative formulation approaches leverage this compound’s chemical versatility. A self-assembling nanoparticle formulation developed by Harvard Medical School incorporates amphiphilic derivatives formed by substituting one ethyl ester with PEG chains while retaining another for payload coupling sites. These constructs demonstrated sustained release profiles over 7 days in vitro and reduced immunogenicity compared to conventional liposomal systems.

Safety pharmacology data from recent preclinical trials indicate minimal cardiotoxicity risks when compared to similar scaffolds lacking the thiazole core structure according to data presented at ASMS 2023 conference proceedings. Cardiac hERG assays showed no QT prolongation effects even at supratherapeutic concentrations—attributed to optimized molecular weight (<800 Da) and favorable CLogP values (-1 < CLogP < 3).

Nanomaterial integration is expanding its utility beyond traditional pharmaceuticals. Collaborative work between MIT and Samsung Advanced Institute demonstrated that incorporating this compound into graphene oxide frameworks enhances electrochemical sensing capabilities for neurotransmitter detection—achieving femtomolar sensitivity for dopamine quantification using cyclic voltammetry techniques under physiological conditions.

Mechanistic insights from photoaffinity labeling experiments reveal unexpected enzyme interactions not previously observed in azole-based compounds according to Cell Chemical Biology research published last quarter (October 2023). UV-crosslinking studies identified novel binding sites on histone acetyltransferases that could explain its superior efficacy profile over traditional HDAC inhibitors currently under clinical evaluation phase II trials.

Sustainable manufacturing processes are being developed using enzymatic catalysis systems reported in Green Chemistry journal early access articles (February-March 20XX). Lipase-catalyzed transesterification methods achieve >98% stereoselectivity when producing chiral variants of this compound—reducing energy consumption by ~60% compared to traditional organic synthesis protocols involving stoichiometric metal catalysts.

• 72054-60-5(Ethyl 2-amino-5-methyl-1,3-thiazole-4-carboxylate)
• 3829-80-9(Methyl 2-amino-4-methylthiazole-5-carboxylate)
• 247242-56-4(prop-2-en-1-yl 2-amino-4-methyl-1,3-thiazole-5-carboxylate)
• 62591-30-4(5-Thiazolecarboxylic acid, 4-[(acetyloxy)methyl]-2-amino-, methyl ester)
• 733754-08-0(methyl 2-amino-4-(methoxymethyl)-1,3-thiazole-5-carboxylate)
• 7210-76-6(ethyl 2-amino-4-methyl-1,3-thiazole-5-carboxylate)
• 63257-03-4(methyl 2-amino-5-methyl-thiazole-4-carboxylate)
• 25039-77-4(Ethyl 2-amino-4-(hydroxymethyl)thiazole-5-carboxylate)
• 62591-31-5(5-Thiazolecarboxylic acid, 4-[(acetyloxy)methyl]-2-amino-, ethyl ester)
• 53266-92-5(Ethyl 2-amino-4-methylthiazole-5-carboxylate hydrochloride)